kidney disease glp 1 GLP-1 agonists in the treatment of chronic in type 2 diabetes and obesity GLP-1 Receptor Agonists in the

The STEP 1 trial for semaglutide 2.4mg demonstrated a mean body weight reduction of approximately 14.9% over 68 weeks in adults with obesity. The SURMOUNT-1 trial for tirzepatide showed reductions of up to 22.5% at the highest dose. These are outcomes that approach the efficacy of bariatric surgery in some patient cohorts

Losing the Weight Loss Meds: A 10-Week Playbook for Stopping GLP-1 Medications Without Regaining the Weight [Wyatt MD, Holly R., Hill PhD, James O.] on Amazon.com

At Laser Lipo and Veins, we offer expert guidance, personalized treatment plans, and ongoing support to help you reach your goals safely and effectively

100% refreshing

By connecting you with licensed providers who can prescribe personalized treatmentsincluding compounded semaglutide or tirzepatide shipped from inspected pharmacieswe ensure your journey is medically supervised every step of the way